Home
News
Create
Screeners
Insights
Remus Pharmaceuticals
765.
25
-14.00
(-1.80%)
Market Cap
₹901.77 Cr
PE Ratio
19.89
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-1.80%
1M
+9.93%
6M
+7.85%
1Y
-61.16%
5Y
-67.68%
View Company Insights
Latest news about Remus Pharmaceuticals
Remus Pharmaceuticals appoints Bhavik Shah as CFO effective July 9, 2026
7 days ago
Remus Pharmaceuticals appointed Bhavik Shah as Chief Financial Officer effective July 9, 2026, following Anjali Shah's resignation. Shah, a Chartered Accountant with over 20 years of experience, will oversee finance, accounts, and regulatory compliance. The Board approved the appointment based on committee recommendations.
Remus Pharmaceuticals unit faces IRS penalty of USD 14,247.38
9 days ago
Remus Pharmaceuticals FY26 net profit rises 20% to ₹46 crore
May 29, 2026
Remus FY26 PAT rises 20% to ₹46.17 Cr, declares dividend
May 22, 2026
Remus Pharmaceuticals posts FY26 earnings call audio
May 22, 2026
More news about Remus Pharmaceuticals
21
May 26
Remus Pharmaceuticals appoints Tapan Shah as Secretarial Auditor
Remus Pharmaceuticals Limited appointed Mr. Tapan Shah as Secretarial Auditor for FY 2026-2027 on May 20, 2026. The Board approved the appointment based on the Audit Committee's recommendation. Mr. Shah brings over two decades of experience in corporate and regulatory compliance.
21
May 26
Remus Pharmaceuticals appoints Sharp & Tannan as Internal Auditor
Remus Pharmaceuticals Limited has appointed Sharp & Tannan Associates as its Internal Auditor for the financial year 2026-27. The Board of Directors approved the appointment on May 20, 2026, based on the Audit Committee's recommendation. The firm, established in 1934, brings extensive experience in internal audit and assurance services.
10
Nov 25
Remus Pharmaceuticals Posts 34% Surge in H1 Net Profit, Revenue Soars 47%
Remus Pharmaceuticals, a key player in the Indian pharmaceutical sector, has announced robust financial results for the first half of the fiscal year. The company's consolidated revenue increased by 47% to ₹4,000.00 crore, while net profit rose by 34% to ₹175.00 crore compared to the same period last year. EBITDA grew by 27% to ₹269.00 crore. However, the EBITDA margin contracted by 110 basis points to 6.70% from 7.80% in the previous year.
Remus Pharmaceuticals
765.
25
-
14.
00
(-
1.
80
%)
1 Year Returns:
-61.16%
Industry Peers
Sun Pharmaceutical
1,862.10
(-
0.
02
%)
Divis Laboratories
6,573.00
(-
0.
09
%)
Torrent Pharmaceuticals
4,604.70
(-
0.
33
%)
Cipla
1,450.60
(-
1.
01
%)
Dr Reddys Laboratories
1,346.40
(-
0.
79
%)
Zydus Life Science
1,112.20
(-
0.
04
%)
Lupin
2,397.60
(-
0.
88
%)
Mankind Pharma
2,516.30
(-
1.
15
%)
Aurobindo Pharma
1,552.40
(-
1.
67
%)
Laurus Labs
1,488.90
(-
1.
88
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar